Dyne Therapeutics, Inc. (DYN): Shareholders' Equity
$972.13M
As of 2025-12-31
$702.15M
As of 2026-06-30
+56.8%
3-year compound annual growth
+23.2%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $972.13M | +54.3% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $629.84M | +589.9% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $91.29M | -63.8% | 2026-03-02, Balance as of period end |
| 2022-12-31 | $252.36M | -31.5% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $368.20M | +7.5% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $342.37M | n/m | 2022-03-10, Balance as of period end |
| 2019-12-31 | $14.04M | n/a | 2021-03-04, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | 2025-12-31 | $972.13M | +54.3% |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | -$98.00M | n/m |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $715.50M | -14.9% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $631.00M | +30.1% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | $602.69M | -20.1% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $693.11M | -11.0% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $1.02B | -3.4% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $870.22M | +32.0% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $1.19B | -22.6% |
Compare DYN, INDV, ZLAB, RCUS side by side · Screen every company in Pharmaceutical Preparations ↗